Fluzone High-Dose
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07192458 | Sep 2025 → Dec 2028 expected | influenza | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05947071 | Sep 2024 → Jul 2027 expected | disease related to solid organ transplantation, influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06291857 | Dec 2024 → Dec 2025 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT03330132 | Oct 2017 → Dec 2025 | influenza | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT02868970 | Feb 2017 → Jul 2021 | — | Canadian Immunization Research Network | Completed | No outcome recorded |
| Phase 4 | NCT02908269 | Sep → Dec 2016 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT02563093 | Sep → Dec 2015 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01946438 | Sep → Dec 2013 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05663463 | Sep 2023 → Jun 2025 | disease related to solid organ transplantation | University of Minnesota | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 2 | NCT02831751 Comparator | Apr → Jul 2016 | primary viral infectious disease, respiratory tract infectious disorder | Medicago | Completed | No outcome recorded |
| Phase 2 | NCT00551031 Comparator | Oct 2007 → Jun 2008 | influenza | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04143451 Comparator | Oct 2019 → Sep 2022 | influenza | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT04101838 Comparator | Apr 2021 → May 2026 overdue | influenza | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03722589 Comparator | Sep 2018 → Jul 2020 | influenza | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT03603509 Comparator | Aug 2018 → Jan 2019 | influenza | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03183908 Comparator | Aug 2017 → Feb 2019 | — | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT01691339 Comparator | Sep → Nov 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01430819 Comparator | Sep 2011 → Feb 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone High-Dose | “0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.” NCT03330132 ↗17“Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs.” NCT05947071 ↗ “Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.” NCT02868970 ↗ “Fluzone High-Dose (Influenza Vaccine) for intramuscular use is an inactivated influenza vaccine” NCT07192458 ↗ “Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain” NCT06291857 ↗ “Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation” NCT01430819 ↗ “Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation” NCT01691339 ↗ “Fluzone® High-dose Group” NCT00551031 ↗ |
| Known as | Fluzone HD | “High-dose influenza vaccine (Fluzone® HD)” NCT03183908 ↗ |
| Known as | Fluzone High-Dose (2012-2013 Formulation) | “Fluzone® High-Dose (2012-2013 Formulation)” NCT01691339 ↗ |
| Known as | Fluzone High-Dose, Influenza Vaccine | “Fluzone® High-Dose, Influenza Vaccine” NCT02563093 ↗1“Fluzone® High-Dose Influenza Vaccine” NCT02908269 ↗ |
| Known as | Fluzone High-Dose, Influenza Virus Vaccine | “Fluzone® High-Dose, Influenza Virus Vaccine” NCT01946438 ↗ |
| Known as | Fluzone Trivalent High-Dose | “Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain” NCT03722589 ↗ |
| Modality | Vaccine | “trivalent inactivated vaccine (TIV)” NCT00551031 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular (IM)” NCT00551031 ↗ |